Rapamycin reduces seizure frequency in tuberous sclerosis complex.
The authors present a 10-year-old girl with tuberous sclerosis complex who has been receiving rapamycin for 10 months for seizure control. She was started at 0.05 mg/kg/d and titrated to an effective dose of 0.15 mg/kg/d. There was a dramatic reduction in seizure frequency with rapamycin therapy. Further studies are needed to objectively investigate the benefits of rapamycin in tuberous sclerosis complex and to clarify its mechanism of seizure control.
Muncy
Jennifer
J
The University of Texas Health Science Center Houston, Texas, USA.
Butler
Ian J
IJ
Koenig
Mary Kay
MK
D000927:Anticonvulsants / Q000008:administration & dosage* / Q000009:adverse effects; D002220:Carbamazepine / Q000031:analogs & derivatives / Q000627:therapeutic use; D002540:Cerebral Cortex / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D002648:Child; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D005632:Fructose / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects; D008279:Magnetic Resonance Imaging; D019635:Neurosurgical Procedures; D010291:Paresis / Q000209:etiology / Q000503:physiopathology; D012640:Seizures / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology; D020123:Sirolimus / Q000008:administration & dosage* / Q000009:adverse effects; D000077236:Topiramate; D016896:Treatment Outcome; D014402:Tuberous Sclerosis / Q000150:complications* / Q000473:pathology / Q000503:physiopathology; D014777:Virus Diseases / Q000139:chemically induced / Q000276:immunology
D000927:Anticonvulsants; D007166:Immunosuppressive Agents; C476610:oxcarbamazepine; D000077236:Topiramate; D005632:Fructose; D002220:Carbamazepine; D020123:Sirolimus